Identification and Characterization of a Small Molecule Bcl-2 Functional Converter

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer cells evade apoptosis by overexpressing the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2).
• High Bcl-2 levels sequester pro-apoptotic proteins, halting the cell death machinery and conferring therapeutic resistance.

Purpose of the Study:

• To discover and characterize a novel small molecule that targets Bcl-2.
• To develop a new therapeutic strategy for Bcl-2-expressing cancers.

Main Methods:

• Identification of the small molecule BFC1108 (5-chloro-N-(2-ethoxyphenyl)-2-[(4-methoxybenzyol)amino]benzamide).
• In vitro and in vivo studies to assess Bcl-2 conformational changes and apoptotic induction.
• Evaluation of BFC1108 efficacy in triple-negative breast cancer xenograft models and metastasis inhibition.

Main Results:

• BFC1108 targets Bcl-2, converting it into a pro-apoptotic protein.
• Bcl-2 overexpression potentiates BFC1108's apoptotic effect.
• BFC1108 induces a Bcl-2 conformational change, exposing its BH3 domain in vitro and in vivo.
• BFC1108 suppressed tumor growth in triple-negative breast cancer xenografts and inhibited lung metastasis.

Conclusions:

• BFC1108 is a novel small molecule Bcl-2 functional converter.
• This molecule effectively induces apoptosis in Bcl-2-expressing cancers, offering a new therapeutic avenue.